A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
Clinical trial NCT02387957 · TERMINATED
Trial details
- NCT number
- NCT02387957
- Sponsor
- Ophthotech Corporation
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-04-26
- Primary completion
- 2017-01-01
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.